MMS Holdings and Medidata Solutions Form Strategic Alliance
The data-driven Contract Research Organization (CRO) MMS Holdings, along with Medidata Solutions, being the leader in clinical trial technology, announced in June 2022 a strategic alliance. Its goal was to deliver clients an integrated set of Medidata solutions specifically catering for clinical data management (CDM) and decentralized clinical trials (DCTs).
Rave EDC technology and the unified platform from Medidata formed the core components of this alliance. These technologies have become widely recognized for their capability to optimize gathering, handling, and analysis of clinical trial data. In that way, this collaboration meant to increase process accuracy, efficiency, and compliance with international regulatory requirements. With that, MMS Holdings broadened the scope of its services. This would be an opportunity to support customers using conventional clinical trial strategies as well as more creative, decentralized trial techniques.
The Rave EDC system is the most vital tool for ensuring clinical trial data integrity as it allows real-time entry, validation, and visualization of clinical trials. Moreover, Medidata's integrated platform has helped MMS Holdings increase its ability to manage data because every aspect of the trial, from planning and collection to analytics and reporting, is understood on a unified platform.
By incorporating Medidata's advanced technological systems, MMS Holdings significantly enhanced its market value and attracted a broader base of customers whose companies seek a better way of managing their clinical trial business through innovative approaches. The services offered by the agreement would address a whole range of new, as well as existing, requirements for clinical trials, and thus differentiated MMS from competitors.
